Introduction {#s1}
============

G protein-coupled receptors (GPCRs) comprise nature's largest family of signaling receptors and an important class of therapeutic targets ([@bib39]; [@bib56]). GPCRs are so-named because a major mechanism by which they mediate transmembrane signaling is through ligand-dependent activation of heterotrimeric G proteins that act as intracellular signal transducers ([@bib19]; [@bib25]; [@bib61]; [@bib65]; [@bib66]). This conserved signaling cascade invariably requires one additional component, an 'effector' protein which is regulated by the G protein to convey the signal downstream ([@bib12]; [@bib19]; [@bib56]). Ligand-activated GPCR - G protein - effector cascades were thought for many years to be restricted to the plasma membrane, with endocytosis considered only in the context of signal termination and homeostatic down-regulation of receptors. This view has expanded over the past several years, driven by accumulating evidence that ligand-dependent GPCR and G protein activation processes can also occur from internal membrane compartments including endosomes ([@bib13]; [@bib31]; [@bib32]; [@bib40]; [@bib42]; [@bib43]; [@bib78]).

The beta-2 adrenergic receptor (β2AR) provides a clear example, and is generally considered a model for the GPCR family more broadly ([@bib39]; [@bib56]). β2ARs initiate signaling in response to binding of an agonist ligand by activating (\'coupling\' to) the stimulatory heterotrimeric G protein, Gs, at the plasma membrane. β2ARs then internalize through agonist-dependent accumulation into clathrin-coated pits, efficiently recycle and transit continuously between the plasma membrane and endosomes in the prolonged presence of agonist ([@bib81]; [@bib80]). Agonist-induced clustering of β2ARs into coated pits, the process initiating this cycle, is promoted by receptor phosphorylation and binding to β-arrestins at the plasma membrane ([@bib15]; [@bib21]). These events were shown previously to inhibit β2AR coupling to Gs ([@bib41]), and β2AR inactivation was recognized to precede removal from the cell surface even before this mechanistic elucidation ([@bib24]). Accordingly, it was believed for many years that β2ARs are unable to engage G proteins once internalized. This view changed with the finding that β2ARs reacquire functional activity shortly after arriving in the limiting membrane of early endosomes, and then activate Gs again from this location ([@bib30]). A number of GPCRs have now been shown to activate Gs after endocytosis, initiating a discrete 'second wave' of downstream signaling which varies in magnitude and duration depending (in part) on the residence time of activated receptors in the endocytic network ([@bib31]; [@bib42]; [@bib73]; [@bib74]; [@bib77]; [@bib78]).

Gs transduces downstream signaling by stimulating adenylyl cyclases (ACs) to produce cyclic AMP (cAMP), an important diffusible mediator ([@bib43]; [@bib67]; [@bib70]), and studies of cAMP signaling provided much of the initial evidence supporting the potential of GPCRs to mediate ligand-dependent signaling via G proteins after endocytosis ([@bib5]; [@bib10]; [@bib16]; [@bib36]; [@bib48]; [@bib58]). Nine transmembrane AC isoforms are conserved in mammals, each stimulated by Gs but differing in regulation by other G proteins and signaling intermediates, and multiple AC isoforms are typically coexpressed in tissues ([@bib57]; [@bib66]; [@bib82]). Biochemical and structural aspects of regulated cAMP production by ACs have been extensively studied but much less is known about the cellular biology of ACs.

According to the present understanding, GPCR-stimulated cAMP production requires all three 'core' components of the signaling cascade -- the GPCR, Gs and AC -- to be in the same membrane bilayer ([@bib20]). Whereas GPCRs and Gs are well known to undergo dynamic redistribution between the plasma membrane and endocytic membranes ([@bib1]; [@bib26]; [@bib31]; [@bib45]; [@bib80]; [@bib83]), the subcellular localization and trafficking properties of transmembrane ACs remain largely unknown. Nevertheless, adenylyl cyclase activity was noted on intracellular membranes many years ago ([@bib9]) and more recent studies have implicated several AC isoforms in GPCR-regulated cAMP production from endomembrane compartments ([@bib5]; [@bib6]; [@bib16]; [@bib27]; [@bib36]; [@bib78]). Key knowledge gaps at the present frontier are how ACs localize to relevant internal membranes, if the subcellular localization of ACs is selective between isoforms, and if this localization is regulated. Here we report initial inroads into this frontier by demonstrating the dynamic and isoform-specific endocytic trafficking of AC9, and its ligand-dependent regulation through Gs.

Results {#s2}
=======

Regulated and isoform-selective trafficking of AC9 to endosomes {#s2-1}
---------------------------------------------------------------

Human embryonic kidney (HEK293) cells comprise a well established model system for investigating GPCR signaling via the cAMP cascade, particularly signaling initiated by β2ARs which are endogenously expressed in these cells ([@bib79]). The β2AR stimulates cAMP production primarily from the plasma membrane, with endosomal activation contributing a relatively small but functionally significant fraction ([@bib30]; [@bib76]). In a similar vein, AC3 and AC6 are the most highly expressed AC isoforms and are major producers of global cAMP in these cells, while AC1 and AC9 transcripts are expressed at only moderately reduced levels and comparable to one another ([@bib60]). This prompted us to ask whether AC1 and/or AC9 might be relevant to generating the fraction of cellular cAMP produced by β2AR activation in endosomes.

As a first step to investigate this hypothesis, we examined the subcellular localization of AC1 and AC9 using a recombinant epitope tagging strategy, beginning with AC1 because this isoform was shown previously to tolerate an N-terminal Flag tag ([@bib8]). When expressed in HEK293 cells, Flag-tagged AC1 (Flag-AC1) localized primarily to the plasma membrane, similar to a co-expressed HA-tagged β2AR construct (HA-β2AR). Application of the β-adrenergic agonist isoproterenol promoted HA-β2ARs to redistribute within minutes to cytoplasmic punctae, as described previously, but Flag-AC1 remained at the plasma membrane ([Figure 1A](#fig1){ref-type="fig"}). While clearly resolved in confocal sections, this difference in localization was sufficiently strong to be evident in lower-magnification widefield images surveying many cotransfected cells ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). We assessed reproducibility of this effect in two ways. First, we determined the number of internal punctae per cell in which HA-β2AR and Flag-AC1 colocalized. Second, we determined the fraction of cells visualized in each microscopic field that contained at least 10 such punctae. Both metrics verified selective internalization of the β2AR but not AC1 ([Figure 1C and D](#fig1){ref-type="fig"}, left set of bars).

![β2AR activation promotes redistribution of AC9 but not AC1.\
(**A**) Representative confocal imaging of HEK293 cells coexpressing HA-β2AR and Flag-AC1 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µm. (**B**) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µm. (**C**) Quantification of internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see [Figure 1---figure supplement 1D and E](#fig1s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**D**) Quantification of cells with \>10 internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see [Figure 1---figure supplement 1D andE](#fig1s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**E--F**) Representative confocal imaging of HEK293 cells expressing Flag-AC1 (**E**) or Flag-AC9 (**F**) after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 8 µM. (**G--H**) Representative confocal imaging of HEK293 cells expressing Flag-AC1 (**G**) or Flag-AC9 (**H**). Cells were stimulated with 100 nM isoproterenol for 30 min with or without 15 min of pretreatment with 10 µM alprenolol. (**I**) Representative confocal images of primary culture human airway smooth muscle cells immunostained for endogenous AC9 after treatment with 10 µM isoproterenol or control for 30 min. Scale Bar is 16 µm.](elife-58039-fig1){#fig1}

We applied a similar tagging strategy to AC9 and verified that Flag tagging also does not disrupt the functional activity of AC9 ([Figure 1---figure supplement 1A,B](#fig1s1){ref-type="fig"}). Flag-AC9 localized predominantly in the plasma membrane in the absence of agonist, similar to Flag-AC1. However, after application of isoproterenol, Flag-AC9 redistributed to intracellular punctae, the majority of which also contain internalized HA-β2AR ([Figure 1B](#fig1){ref-type="fig"}). Punctate redistribution of both Flag-AC9 and HA-β2AR was also evident in lower-magnification widefield images ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}) and was verified quantitatively ([Figure 1C and D](#fig1){ref-type="fig"}, right set of bars). AC9 labeled in its C-terminal cytoplasmic domain with GFP (AC9-GFP) also redistributed, enabling live-cell confocal imaging which revealed mobile AC9-containing endosomes ([Video 1](#video1){ref-type="video"}). These results indicate that AC9 traffics dynamically to endosomes containing β2ARs, this trafficking is isoform-specific because AC1 remains in the plasma membrane, and it is regulated because AC9 accumulation in endosomes is increased by β2AR activation.

###### This movie shows a confocal image series of AC9-EGFP overexpressed in a HEK293 cell.

Cell was treated with 10 µM isoproterenol added at t = 0 in the time stamp. AC9 recruitment to internal puncta is observed over the course of 30 min.

Isoproterenol also stimulated selective internalization of Flag-AC9 in the absence of recombinant β2AR overexpression ([Figure 1E and F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}) and this effect was blocked by the β-adrenergic antagonist alprenolol ([Figure 1G and H](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). These results indicate that endogenous β2AR activation is sufficient to stimulate AC9 trafficking and this is not an off-target drug effect. AC9, and ACs in general, are naturally expressed in low abundance. We were unable to reliably detect endogenous AC9 in HEK293 cells using available antibodies, but endogenous AC9 was detectable in primary human airway smooth muscle cells that naturally coexpress β2ARs ([@bib3]). Endogenous AC9 immunoreactivity localized in these cells primarily to the plasma membrane under basal conditions, and its localization to internal punctae increased after isoproterenol application ([Figure 1I](#fig1){ref-type="fig"}). These results suggest that the trafficking behavior revealed by study of recombinant, tagged AC9 is relevant to the native protein.

AC9 traffics via a similar pathway as β2AR but is differentially regulated {#s2-2}
--------------------------------------------------------------------------

Internalized β2ARs accumulate in endosomes marked by Early Endosome Antigen 1 (EEA1) and agonist-dependent activation of Gs by the β2AR occurs on this compartment ([@bib30]). We verified isoform-specific localization of Flag-AC9 but not Flag-AC1 to EEA1-marked endosomes by confocal microscopy ([Figure 2A and B](#fig2){ref-type="fig"}) and then applied anti-EEA1 immunoisolation ([@bib11]; [@bib23]; [@bib71]) to purify these endosomes and probe their composition. Coexpressed HA-β2AR and Flag-AC9 were enriched in the endosome fraction prepared from isoproterenol-treated cells, as detected by immunoblot analysis and verified quantitatively across multiple experiments. In contrast, HA-β2AR but not Flag-AC1 was enriched in parallel isolations from cells co-expressing HA-β2AR and Flag-AC1, with similar levels of overall expression across both cell populations verified in cell lysates ([Figure 2C,D](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Documenting separation efficiency and fraction purity, the endosome fraction recovered \~34% of total cellular EEA1 but [\<]{.ul}5% of Golgi, endoplasmic reticulum, or plasma membrane markers ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}).

![AC9 undergoes dynamin-dependent endocytosis and accumulates in endosomes marked by EEA1.\
(**A--B**) Representative confocal images of HEK293 cells expressing Flag-AC1 (**A**) or Flag-AC9 (**B**) after treatment with 10 µM isoproterenol or control for 30 min and stained for endogenous EEA1. Scale bar is 8 µm. (**C**) Representative western blot of a fraction isolated using antibodies to EEA1. Lanes 1--2 correspond to control HEK293 cells, lanes 3--4 to cells coexpressing Flag-AC9 and HA-β2AR, and lanes 5--6 to cells coexpressing Flag-AC1 and HA-β2AR. (**D**) Quantification of recovery of HA-β2AR, Flag-AC9 and Flag-AC1 in the endosome fraction relative to cell lysate. \[mean ± SEM; n = 7 experiments\]. \*\*p\<0.01 by two-tailed t-test. (**E**) Representative western blot of the surface exposed fraction isolated by surface labeling with Sulfo-NHS-biotin and purified with streptavidin. Lanes 1--2 correspond to cells coexpressing Flag-AC9 and HA-β2AR, and lanes 3--4 to cells coexpressing Flag-AC1 and HA-β2AR. (**F**) Quantification of recovery of HA-β2AR, Flag-AC9 and Flag-AC1 in the surface biotinylated fraction relative to total cell lysate. \[mean ± SEM; n = 7 experiments\]. \*\*p\<0.01 by two-tailed t-test. (**G**) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Cells were treated with DMSO for 15 min prior to agonist exposure. (**H**) Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field images (see [Figure 2---figure supplement 1D and E](#fig2s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**I**) Representative confocal images of HEK293 cells coexpressing HA-β2AR and Flag-AC9 after treatment with 10 µM isoproterenol or control for 30 min. Cells were treated with DYNGO-4a for 15 min prior to agonist exposure. (**J**) Quantification of cells with \>10 internal puncta that are β2AR or AC1/9 positive, taken from wide field images (see [Figure 2---figure supplement 1D and E](#fig2s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test.](elife-58039-fig2){#fig2}

As a distinct and additional biochemical approach to verify these trafficking properties, we used cell surface biotinylation to assess protein depletion from the plasma membrane ([@bib17]; [@bib84]). Isoproterenol produced a marked reduction of Flag-AC9 in the surface-biotinylated fraction but Flag-AC1 was unchanged, and surface HA-β2AR decreased after isoproterenol application irrespective of whether AC1 or AC9 was coexpressed ([Figure 2E,F](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). These observations independently demonstrate isoform-specific trafficking of AC9 from the plasma membrane to endosomes, regulated coordinately with endocytosis of the β2AR.

A characteristic property of the conserved, clathrin-dependent pathway mediating β2AR endocytosis is that it also requires dynamin, an endocytic GTPase which can be acutely inhibited by the cell-permeant small molecule DYNGO-4a ([@bib30]; [@bib44]; [@bib47]). Whereas isoproterenol promoted both Flag-β2AR and AC9-GFP to accumulate in endosomes in the vehicle (0.1% DMSO) control condition ([Figure 2G,H](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1D](#fig2s1){ref-type="fig"}), endosomal accumulation of both proteins was blocked in the presence of DYNGO-4a ([Figure 2I and J](#fig2){ref-type="fig"}, and [Figure 2---figure supplement 1E](#fig2s1){ref-type="fig"}). These results further support the hypothesis that regulated AC9 trafficking to endosomes utilizes a shared membrane pathway and mechanism relative to regulated endocytosis of the β2AR, and many other GPCRs.

Despite these similarities, AC9 and β2AR were found to traffic independently. An early clue to this distinction was that brief exposure of cells outside of the tissue culture incubator (see Materials and methods) inhibits AC9 trafficking but β2AR trafficking is resistant to this environmental stress. While we still do not fully understand the basis for this difference, it focused our attention on investigating the mechanism of AC9 traffic control in detail.

AC9 trafficking is stimulated by GPCRs coupled to Gs but not Gi {#s2-3}
---------------------------------------------------------------

We first asked if the β2AR is unique in its ability to stimulate endosomal accumulation of AC9 or if AC9 trafficking can be stimulated by another Gs-coupled GPCR. To do so we focused on the vasopressin-2 receptor (V2R), a Gs-coupled GPCR which also undergoes agonist-induced trafficking to early endosomes but is not endogenously expressed in HEK293 cells ([@bib4]). The V2R is of particular interest because this GPCR, unlike the β2AR, has been shown to produce a sustained cAMP response via Gs that is associated with slow recycling and binding to β-arrestin in endosomes ([@bib29], [@bib14]; [@bib35]; [@bib52]; [@bib73]). When examined in cells not transfected with recombinant V2Rs, Flag-AC9 remained in the plasma membrane irrespective of the presence of the V2R agonist arginine vasopressin (AVP) as expected ([Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}). However, in cells coexpressing HA-V2R, AVP stimulated the redistribution of both Flag-AC9 and HA-V2R to a shared population of endosomes ([Figure 3A,D,E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). AVP-stimulated endocytosis of both proteins was confirmed by surface biotinylation ([Figure 3F,G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}). These results indicate that the ability of GPCR activation to promote trafficking of AC9 to endosomes is not unique to the β2AR. Rather, it appears to be a shared property of GPCRs which activate Gs.

![Gs but not Gi -coupled GPCRs promote AC9 trafficking.\
(**A--C**) Representative confocal imaging of HEK293 cells coexpressing Flag-AC9 and HA-V2R (**A**), HA-MOR (**B**), or HA-V2R-trunc (**C**), after treatment with 10 µM agonist (AVP or DAMGO) or control for 30 min. Scale Bar is 8 µm. (**D**) Quantification of internal puncta that are V2R, MOR, V2R-T, or AC1/9 positive, taken from wide field images (see [Figure 3---figure supplement 1D, E and F](#fig3s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**E**) Quantification of cells with \>10 internal puncta that are V2R, MOR, V2R-T or AC1/9 positive, taken from wide field images (see [Figure 3---figure supplement 1D, E and F](#fig3s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**F**) Representative western blot of the surface biotinylated fraction from HEK293 cells coexpressing HA-V2R and Flag-AC9 (lanes 1--2), HA-V2R-T and Flag-AC9 (lanes 3--4), or HA-MOR and Flag-AC9 (lanes 5--6). (**G**) Recovery of tagged protein in the surface biotinylated fraction relative to the total cell lysate as seen in (**F**) \[mean ± SEM; n = 7 experiments\]. \*\*p\<0.01 by two-tailed t-test.](elife-58039-fig3){#fig3}

We next asked if the ability to stimulate AC9 trafficking extends to GPCRs that couple to other heterotrimeric G proteins. We focused on the µ-opioid receptor (MOP-R or MOR) because this GPCR transits a similar early endocytic pathway as the β2AR ([@bib33]) but activates Gi rather than Gs ([@bib34]), and because opioid receptors have been shown explicitly to undergo ligand-dependent activation in endosomes ([@bib64]). Application of the µ-opioid agonist \[D-Ala^2^, N-MePhe^4^, Gly-ol\]-enkephalin (DAMGO) stimulated transfected HA-MOR to accumulate in endosomes, as shown previously, while Flag-AC9 remained in the plasma membrane ([Figure 3B,D,E](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}). We verified selective internalization of HA-MOR, but not Flag-AC9, by surface biotinylation ([Figure 3F,G](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). These results suggest that the ability to stimulate AC9 trafficking to endosomes is a property specific to GPCRs which couple to Gs relative to Gi.

We then returned to the V2R, coexpressing a mutant version truncated in its C-terminal cytoplasmic tail. This mutant V2R (HA-V2R-T) retains the ability to activate Gs at the plasma membrane but internalizes less efficiently after agonist-induced activation, promotes β-arrestin recruitment to endosomes less strongly and recycles more rapidly ([@bib29]; [@bib28]; [@bib52]). Despite visibly reduced internalization of HA-V2R-T after agonist application ([Figure 3C,D,E](#fig3){ref-type="fig"}), Flag-AC9 internalization was still observed ([Figure 3C,D,E](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1F](#fig3s1){ref-type="fig"}) and this was confirmed by surface biotinylation ([Figure 3F,G](#fig3){ref-type="fig"}). These results suggest that Gs-coupled GPCRs share the ability to stimulate AC9 trafficking, irrespective of differences in receptor trafficking kinetics or binding to β-arrestin in endosomes.

AC9 trafficking is not dependent on cytoplasmic cAMP or adenylyl cyclase activity {#s2-4}
---------------------------------------------------------------------------------

A possible basis for such shared control of AC9 trafficking is through cAMP elevation that occurs downstream of Gs activation. To test this, we applied the diterpene drug forskolin (FSK) to stimulate cytoplasmic cAMP production independently from the receptor or Gs. While AC9 is relatively insensitive to activation by FSK, other AC isoforms that are major contributors to cAMP production in HEK293 cells (such as AC3 and AC6) are sensitive, making FSK an effective stimulus of overall cAMP elevation ([@bib2]; [@bib60]). FSK did not cause detectable internalization of either HA-β2AR or Flag-AC9 assessed by imaging ([Figure 4---figure supplement 1A,C,D,I](#fig4s1){ref-type="fig"}) or surface biotinylation ([Figure 4---figure supplement 1E,F](#fig4s1){ref-type="fig"}). Further, as expected, Flag-AC1 remained in the plasma membrane irrespective of the presence of FSK ([Figure 4---figure supplement 1B--F,J](#fig4s1){ref-type="fig"}). This was also true in the combined presence of 3-isobutyl-1-methylxanthine (IBMX), a phosphodiesterase inhibitor which enhances FSK-induced cAMP elevation in the cytoplasm ([Figure 4---figure supplement 1H](#fig4s1){ref-type="fig"}).

As an independent approach, and to consider the possibility that cAMP exerts local rather than global control, we asked if endosomal accumulation of AC9 requires its own catalytic activity. To test this, we mutated a conserved aspartic acid residue that coordinates a catalytic magnesium in the active site, and which is essential for activity of AC6 ([@bib18]; [@bib72]). We verified that mutating the equivalent residue in AC9 (Flag-AC9-D442A) blocked cAMP production ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), but found that regulated trafficking of Flag-AC9-D442A still occurred ([Figure 4---figure supplement 1G](#fig4s1){ref-type="fig"}). Together, these results indicate that the ability of GPCR-Gs activation to regulate AC9 trafficking is not a consequence of global cytoplasmic cAMP elevation, nor does it require local cAMP production by AC9.

Gs activation is sufficient to promote AC9 trafficking {#s2-5}
------------------------------------------------------

We next investigated whether AC9 internalization is regulated by Gs itself, and did so by introducing a point mutation into the alpha subunit (HA-Gs-Q227L) that renders Gs constitutively active by reducing its rate of intrinsic GTP hydrolysis ([@bib46]). Flag-AC9 localized to the plasma membrane in the absence of agonist when coexpressed with wild type HA-Gs, but coexpression with activated HA-Gs-Q227L resulted in both proteins localizing to internal punctae ([Figure 4A,C,D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2E](#fig4s2){ref-type="fig"}). This effect was specific to AC9 because AC1 remained at the plasma membrane when coexpressed with either HA-Gs or HA-Gs-Q227L ([Figure 4B,C,D](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2F](#fig4s2){ref-type="fig"}). We verified by immunoisolation that both HA-Gs-Q227L and Flag-AC9 accumulate in EEA1-positive endosomes when coexpressed ([Figure 4---figure supplement 2A,B](#fig4s2){ref-type="fig"}), whereas coexpression of HA-Gs-Q227L with Flag-AC1 failed to produce endosome enrichment of either protein ([Figure 4---figure supplement 2C,D](#fig4s2){ref-type="fig"}). Independently supporting a discrete regulatory effect of Gs, application of cholera toxin (CTX) to activate the endogenous cellular complement of Gs resulted in receptor-independent accumulation of Flag-AC9, but not Flag-AC1, in endosomes ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}).

![Gs activation is sufficient to promote AC9 internalization.\
(**A**) Representative confocal imaging of HEK293 cells cells coexpressing Flag-AC9, G~s~β, G~s~γ and either HA-G~s~α (HA-Gs) or HA-G~s~α-CA (HA-GsCA). (**B**) Representative confocal imaging of HEK293 cells coexpressing Flag-AC1, G~s~β, G~s~γ and either HA-G~s~α (HA-Gs) or HA-G~s~α-CA (HA-GsCA). (**C**) Quantification of internal puncta that are Gs or AC1/9 positive, taken from wide field images (see [Figure 4---figure supplement 2C and D](#fig4s2){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**D**) Quantification of cells with \>10 internal puncta that are Gs or AC1/9 positive, taken from wide field images (see [Figure 4---figure supplement 2C and D](#fig4s2){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**E**) Representative western blot of an EEA1+ fraction from HEK293 cells coexpressing Flag-AC9 and HA-Gs (lanes 1 and 3) or Flag-AC9 and HA-GsCA (lanes 2 and 4) and after treatment with 10 µM isoproterenol (lanes 1--2) or control (lanes 3--4) for 30 min. (**F**) Quantification of the fraction of Flag-AC9 and HA-Gs/HA-GsCA recovered in the EEA1+ fraction (**E**) relative to total cell lysate. \[mean ± SEM; n = 3 experiments\] \*p\<0.05 \*\*p\<0.01 by two-tailed t-test.](elife-58039-fig4){#fig4}

The immunoisolation analysis also indicated that constitutive activation of Gs produced a degree of endosomal enrichment of AC9 similar to that produced in response to endogenous β2AR activation with isoproterenol. Further, application of isoproterenol to cells which coexpress HA-Gs-Q227L did not detectably increase the degree of endosomal enrichment observed for either Gs or AC9 ([Figure 4E,F](#fig4){ref-type="fig"}). Together, these results suggest that Gs activation mediated by endogenous β2ARs is fully sufficient to stimulate AC9 trafficking to endosomes, without requiring additional effects of upstream receptor activation or downstream cAMP signaling.

Regulation of AC9 trafficking requires Gs but not β-arrestin {#s2-6}
------------------------------------------------------------

Because Gs activation is sufficient to stimulate accumulation of AC9 in endosomes, we next asked if it is necessary to regulate this trafficking process. To do so, we utilized previously described Gs-knockout (GsKO) cells which lack Gs due to CRISPR-mediated editing of the alpha subunit (GNAS) gene ([@bib63]). Flag-β2AR and AC9-EGFP localized to the plasma membrane of GsKO as well as wild type HEK293 cells. However, AC9-GFP internalization was blocked in GsKO cells while Flag-β2AR still internalized. Moreover, AC9 trafficking was rescued by expression of recombinant HA-Gs ([Figure 5A-D](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1A,B](#fig5s1){ref-type="fig"}). These results indicate that Gs is necessary for regulated trafficking of AC9 but not β2AR.

![Regulation of AC9 internalization requires Gs but not beta-arrestin.\
(**A--B**) Representative confocal imaging of Gs-knockout (GsKO) HEK293 cells coexpressing Flag-β2AR, AC9-EGFP, and either pcDNA3 (**A**) or wild-type HA-Gs rescue (**B**). (**C--D**) Representative confocal imaging of Arrestin2/3 (β-arrestin −1 and 2) double knockout (Arr DKO) cells coexpressing Flag-β2AR, AC9-EGFP, and either pcDNA3 (**C**) or HA-Arrestin three rescue (**D**). (**E**) Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field images (see [Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**F**) Quantification of cells with \>10 internal puncta that are β2AR or AC9 positive, taken from wide field images (see [Figure 5---figure supplement 1A and B](#fig5s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**G**) Quantification of internal puncta that are β2AR or AC9 positive, taken from wide field images (see [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test. (**H**) Quantification of cells with \>10 internal puncta that are Gs or AC1/9 positive, taken from wide field images (see [Figure 5---figure supplement 1C and D](#fig5s1){ref-type="fig"}) \[mean ± SEM; n = 3 experiments, 10 visual fields and 200+ cells per condition\]. \*\*p\<0.01 by two-tailed t-test.](elife-58039-fig5){#fig5}

Stimulation of β2AR endocytosis by agonists is known to depend on β-arrestins ([@bib15]; [@bib21]). Accordingly, we asked if this is also true for AC9. To test this, we used gene-edited HEK293 cells lacking both β-arrestin isoforms (Arrestins 2 and 3, or β-arrestin-1 and β-arrestin-2) ([@bib51]). Isoproterenol-stimulated internalization of HA-β2AR was lost in β-arrestin double-knockout (Arr DKO) cells, as expected, but AC9-EGFP internalization was still observed. Further, expressing recombinant Arrestin 3 (β-arrestin-2) rescued the HA-β2AR trafficking defect without a noticeable change in AC9-EGFP trafficking ([Figure 5E-H](#fig5){ref-type="fig"}, [Figure 5---figure supplement 1C,D](#fig5s1){ref-type="fig"}). These results indicate that AC9 and GPCR trafficking are regulated coordinately but through distinct mechanisms-- with AC9 requiring Gs but not β-arrestin, and the GPCR requiring β-arrestin but not Gs.

Functional evidence for AC9 signaling from endosomes {#s2-7}
----------------------------------------------------

Both AC1 and AC9 are known physiological effectors of β-adrenergic signaling ([@bib57]; [@bib59]; [@bib69]) and both are endogenously expressed in HEK293 cells, despite neither being the primary contributor to global cAMP elevation produced by β2AR activation in this cell type. Nevertheless, analysis by isoform-specific knockdown using siRNA indicated that both AC1 and AC9 make a small but statistically significant contribution to the overall cAMP elevation elicited by activation of endogenous β2ARs. AC1 but not AC9 depletion reduced the FSK-induced cAMP response ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), consistent with AC9 being relatively insensitive to stimulation by FSK ([@bib2]) and verifying specificity of the knockdown approach. Considering that AC9 selectively accumulates in endosomes relative to AC1, we next investigated the hypothesis that AC9 also selectively contributes to the endosome-initiated component of the β2AR-elicited cellular cAMP response.

We tested this hypothesis using a pharmacological approach based on the ability of the membrane-impermeant β2AR antagonist CGP12177 (CGP) to access receptors selectively at the plasma membrane, whereas the membrane-permeant antagonist alprenolol accesses receptors both at the plasma membrane and endosomes ([@bib62]). This approach has been used successfully in previous studies to isolate effects of endosomal activation ([@bib30]; [@bib73]). We validated it in the present study using a conformational biosensor, Nb80-EGFP, which is recruited specifically and reversibly by activated β2ARs in living cells ([@bib30]). Isoproterenol application promoted recruitment of Nb80-GFP both to the plasma membrane and endosomes, and application of excess alprenolol rapidly reversed this activation readout at both locations ([Figure 6A](#fig6){ref-type="fig"}, [Video 2](#video2){ref-type="video"}). Application of CGP, in contrast, reversed Nb80-GFP recruitment only at the plasma membrane but not endosomes ([Figure 6B](#fig6){ref-type="fig"}, [Video 3](#video3){ref-type="video"}).

![AC9 selectively contributes to the β2AR-mediated cAMP response from endosomes.\
(**A**) Recruitment of conformational biosensors to β2AR-containing endosomes is reversed by application of the membrane permeable antagonist alprenolol for 20 min. Scale Bar is 8 µm. See [Video 2](#video2){ref-type="video"} for full image series. (**B**) Recruitment of conformational biosensors to β2AR-containing endosomes is unaffected by application of the membrane impermeable antagonist CGP12177 for 20 min. Scale Bar is 8 µm. See [Video 3](#video3){ref-type="video"} for full image series. (**C**) Quantification of the maximum cAMP response in control and in AC9 siRNA knockdown HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). \[mean ± SEM; n = 4 experiments\] (**D**) Quantification of the maximum cAMP response in control in AC1 siRNA knockdown HEK293 cells pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). \[mean ± SEM; n = 4 experiments\] (**E**) Quantification of the maximum cAMP response in AC3/6KO HEK293 cells due to AC9 overexpression as the delta between the Flag-AC9 and pcDNA3 conditions. Cells were pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). \[mean ± SEM; n = 4 experiments\] (**F**) Quantification of the maximum cAMP response in AC3/6KO HEK293 cells due to AC1 overexpression as the delta between the Flag-AC1 and pcDNA3 conditions. Cells were pretreated with 100 nM isoproterenol and exposed to supersaturating conditions of membrane permeable antagonist (10 µM alprenolol) or membrane impermeable antagonist (10 µM CGP12177). \[mean ± SEM; n = 4 experiments\] (**G**) Model: Ligand binding causes initial signaling event at the PM followed by arrestin-dependent endocytosis of β2AR. AC1 is restricted to the PM but AC9 is dynamically redistributed by a distinct Gs regulated process, and contributes to the β2AR-mediated cAMP response from the endosome.](elife-58039-fig6){#fig6}

###### This movie shows a confocal image series of β2AR (red) and Nb80-EGFP (green) from a HEK293 cell pre-incubated for 20 min with 100 nM isoproterenol.

10 µM alprenolol, added at t = 0 time point indicated in the time stamp, reverses Nb80-EGFP recruitment to β2ARs at both the plasma membrane and endosomes.

###### This movie shows a confocal image series of β2AR (red) and Nb80-EGFP (green) from a HEK293 cell pre-incubated for 20 min with 100 nM isoproterenol.

10 µM CGP12177, added at t = 0 indicated in the time stamp, reverses Nb80-EGFP recruitment to β2ARs at the plasma membrane but not at endosomes.

We next applied this approach to probe the contribution of endosomal β2AR activation to the overall cellular cytoplasmic cAMP response. Both CGP and alprenolol markedly inhibited the isoproterenol-induced cAMP elevation measured at 37 °C in living cells. This verifies that a large fraction of the overall cAMP elevation elicited by endogenous β2AR activation in these cells is initiated from the plasma membrane. However, we also consistently observed a more pronounced inhibition of cellular cAMP elevation following application of alprenolol compared to CGP ([Figure 6C](#fig6){ref-type="fig"}, left set of bars, and [Video 4](#video4){ref-type="video"}). We interpret this difference as a readout of the component of cAMP production initiated from endosomes. Remarkably, this CGP-resistant 'signal gap' was lost after AC9 knockdown but it remained in cells depleted of AC1 ([Figure 6C,D](#fig6){ref-type="fig"}, [Figure 6---figure supplement 1C--H](#fig6s1){ref-type="fig"}).

###### This movie shows an image series of the luminescence-based cAMP biosensor from HEK293 cells that have been treated with control siRNA (columns 1 and 2) or AC9 siRNA (columns 3 and 4).

Cells were preincubated with 100 nM isoproterenol for 20 min prior to imaging, and 10 µM CGP12177 or 10 µM alprenolol were added immediately before imaging, where indicated.

As another test of this hypothesis, and to investigate selectivity under conditions of recombinant AC overexpression (which were necessary for the trafficking studies), we asked if similar selectivity can be observed also using tagged AC isoforms. To do so we utilized gene-edited HEK293 cells lacking both AC3 and AC6 (AC3/6 DKO), which were shown previously to provide a reduced background useful for assessing effects of recombinant AC expression on cellular cAMP ([@bib60]). The increment of isoproterenol-induced cAMP accumulation produced by overexpressing Flag-AC9 in these cells ('AC9 cAMP response') was blocked by alprenolol but not CGP ([Figure 6E](#fig6){ref-type="fig"}). In contrast, the corresponding increment produced by overexpressing Flag-AC1 ('AC1 cAMP response') was blocked by both alprenolol and CGP ([Figure 6F](#fig6){ref-type="fig"}). This verifies that AC9 selectively contributes to cellular cAMP production initiated by β2AR activation in endosomes using recombinant, as well as endogenous AC9.

Discussion {#s3}
==========

The endocytic network is a dynamically regulated system critical for homeostatic integrity of the cell. From the point of view of GPCR-G protein signaling, this network was believed for many years to be silent, functioning only in signal termination and longer-term modulation of surface receptor number. Such homeostatic effects indeed occur, but an accumulating body of evidence supports an expanded view in which internalized GPCRs reacquire the ability to activate G proteins after endocytosis and initiate a second wave of signaling from endomembrane sites ([@bib31]; [@bib42]; [@bib78]). Endosomal signaling depends on the presence of a G protein-regulated effector, but whether or how effectors localize to relevant internal membrane locations has remained a relatively unexplored frontier.

We approached this frontier by focusing on ACs as important effectors of signaling initiated by GPCR - Gs activation. We demonstrate dynamic and regulated trafficking of AC9 to early endosomes. This compartment is known to accumulate a wide variety of GPCRs, and it has been explicitly shown to be a site of Gs activation by the β2AR ([@bib30]). AC9 is widely expressed ([@bib54]), is a physiologically and clinically relevant effector of β2AR-Gs signaling in particular ([@bib59]; [@bib66]; [@bib69]) and is endogenously expressed in the HEK293 model system used in the present study. We also show that AC9, while contributing only a minor fraction to the overall cellular cAMP response elicited by β2AR activation in this system, is necessary to produce a specific endosome-initiated component of the endogenous β2AR-elicited cAMP response. Further, we demonstrate that AC9 is sufficient to increase cAMP production from endosomes when expressed as a recombinant protein. Moreover, we show that AC trafficking is isoform-specific because AC1 does not detectably accumulate in endosomes, nor does AC1 contribute detectably to the endosome-initiated component of cellular cAMP signaling ([Figure 6G](#fig6){ref-type="fig"}).

An important future goal is to identify structural and biochemical determinants of isoform-specific AC trafficking. We note that various isoform-specific protein interactions which impact other aspects of AC organization and function are already known, with AC9 being a particularly well-studied example ([@bib2]). Another important question for future investigation is whether regulated intracellular trafficking is unique to AC9 or more widespread. We favor the latter possibility because a distantly related AC isoform was previously localized to a multivesicular intracellular compartment in *D. discoideum* ([@bib37]). However, in this case, AC trafficking appears to occur through the biosynthetic pathway and it is not known if the AC-containing compartment also contains a relevant GPCR or G protein. We also note that several other transmembrane AC isoforms have been implicated previously in endomembrane cAMP signaling by mammalian GPCRs ([@bib5]; [@bib6]; [@bib16]; [@bib36]; [@bib48]; [@bib78]), and that a distinct AC isoform which lacks any transmembrane domains ('soluble' AC or AC10) has been implicated as well ([@bib27]). Thus we anticipate that AC9 is not the only isoform to exhibit discrete trafficking behavior, and that much remains to be learned along this line. In particular, we note that the localization and trafficking properties of AC3 and AC6-- which are major contributors to overall cAMP production stimulated by β2ARs in HEK293 cells ([@bib60])-- have yet to be delineated.

One possible mechanism of AC9 trafficking to GPCR-containing endosomes is by physical association with the receptor or receptor-G protein complex, and there is previous evidence indicating that AC5 can form a complex including GPCRs ([@bib49]). However, our results provide two lines of evidence indicating that AC9 traffics independently, despite trafficking via a similar dynamin-dependent membrane pathway as the β2AR and in a coordinated manner. First, activation of Gs is sufficient to promote the accumulation of AC9 but not β2AR in endosomes. Second, AC9 trafficking requires Gs but not β-arrestins, whereas the converse is true for trafficking of the β2AR. Accordingly, AC trafficking is likely subject to different modulatory input(s) relative to the trafficking of GPCRs. This is consistent with the difference in environmental sensitivity between AC9 and β2AR trafficking which initially motivated our investigations. However, additional studies will be required to fully elucidate the mechanistic basis for differential control of AC9 trafficking, and to delineate physiological inputs into regulated AC trafficking more broadly. The physiological significance of isoform-specific AC trafficking also remains to be determined, but we note that there is already significant evidence that cAMP produced internally can mediate different downstream signaling effects relative to cAMP produced from the plasma membrane ([@bib50]; [@bib76]).

In closing, to our knowledge the present study is the first to delineate the dynamic endocytic trafficking of a functionally relevant AC isoform, and to identify a role of Gs in regulating the trafficking of a defined AC separately from its catalytic activity. The finding that such AC trafficking is isoform-specific, and regulated separately from its activating GPCR, reveals a new layer of specificity and control in the cAMP system.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                        Designation                                                     Source or reference                    Identifiers                                                               Additional information
  (species) or resource                                                                                                                                                                                                 
  ------------------------------------ --------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------------------- ----------------------------------------
  Cell line (*Homo sapiens*)           HEK293                                                          ATCC                                   CRL-1573; RRID:[CVCL_0045](https://scicrunch.org/resolver/CVCL_0045)      Human embryonic kidney (female)

  Cell line (*Homo sapiens*)           GNAS-knockout                                                   [@bib63]                                                                                                         HEK293 parental

  Cell line (*Homo sapiens*)           Arrestin 2 and 3 double knockout                                [@bib51]                                                                                                         HEK293 parental

  Cell line (*Homo sapiens*)           ADCY 3 and 6 double knockout                                    [@bib60]                                                                                                         HEK293 parental

  Biological sample (*Homo sapiens*)   Human smooth airway muscle cells (HSAMs)                        Prepared from lung biopsy ([@bib75])                                                                             Primary cell culture

  Antibody                             Mouse anti-FLAG (M1)                                            Sigma-Aldrich                          F-3040; RRID:[AB_439712](https://scicrunch.org/resolver/AB_439712)        (1:1000)

  Antibody                             Rabbit anti-Flag                                                Sigma-Aldrich                          F7425; RRID:[AB_439687](https://scicrunch.org/resolver/AB_439687)         (1:1000)

  Antibody                             Mouse anti-HA                                                   Biolegend                              16B12; RRID:[AB_2820200](https://scicrunch.org/resolver/AB_2820200)       (1:1000)

  Antibody                             Goat anti-AC9                                                   Santa Cruz Biotech                     sc-8576; RRID:[AB_2223286](https://scicrunch.org/resolver/AB_2223286)     (1:50)

  Antibody                             Mouse anti-EEA1                                                 Fisher Scientific                      610457; RRID:[AB_397830](https://scicrunch.org/resolver/AB_397830)        (1:1000)

  Antibody                             Mouse anti-Golgin-97                                            Thermo                                 A-21270; RRID:[AB_221447](https://scicrunch.org/resolver/AB_221447)       (1:1000)

  Antibody                             Rabbit anti-calnexin                                            Cell Signaling                         2679P; RRID:[AB_2228381](https://scicrunch.org/resolver/AB_2228381)       (1:1000)

  Antibody                             Mouse anti-Sodium/Potassium ATPase                              Novus Biologicals                      NB300-540SS; RRID:[AB_306023](https://scicrunch.org/resolver/AB_306023)   (1:1000)

  Recombinant DNA reagent (human)      Flag-AC9 (plasmid)                                              [@bib53]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (human)      Flag-AC1                                                        [@bib8]                                                                                                          pcDNA3 backbone

  Recombinant DNA reagent (human)      Flag-AC9-D442A                                                  This study                                                                                                       pcDNA3 backbone

  Recombinant DNA reagent (human)      AC9-EGFP                                                        This study                                                                                                       EGFP-C1 backbone

  Recombinant DNA reagent (human)      HA-B2AR                                                         [@bib80]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (human)      HA-V2R                                                          [@bib55]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (mouse)      HA-MOR                                                          [@bib84]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (human)      HA-V2R-T                                                        [@bib55]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent              Nb80-EGFP                                                       [@bib30]                                                                                                         EGFP-C1 backbone

  Recombinant DNA reagent (human)      HA-G(alpha)s                                                    [@bib30]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (human)      G(beta-1)                                                       [@bib30]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (human)      G(gamma-2)                                                      [@bib30]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent (human)      HA-G(alpha)s-Q227L                                              [@bib46]                                                                                                         pcDNA3 backbone

  Recombinant DNA reagent              pGloSensor-20F                                                  Promega                                E1171                                                                     

  Transfected construct (human)        AC9-siRNA                                                       This study                                                                                                       See Materials and methods for sequence

  Transfected construct (human)        AC1 siRNA                                                       This study                                                                                                       See Materials and methods for sequence

  Chemical compound, drug              Isoprenaline (iso)                                              Sigma-Aldrich                          51-30-9                                                                   

  Chemical compound, drug              Arginine-vasopressin (AVP)                                      Sigma-Aldrich                          113-79-1                                                                  

  Chemical compound, drug              DAMGO, \[D-Ala2, N-Me-Phe4, Gly5-ol\]-Enkephalin acetate salt   Sigma-Aldrich                          E7384                                                                     

  Chemical compound, drug              DYNGO-4a                                                        Abcam Biochemicals                     ab120689                                                                  

  Chemical compound, drug              Alprenolol                                                      Sigma                                  3707-88-5                                                                 

  Chemical compound, drug              CGP12177                                                        Tocris                                 1134                                                                      

  Chemical compound, drug              Forskolin                                                       Sigma-Aldrich                          66575-29-9                                                                

  Chemical compound, drug              3-isobutyl-1-methylxanthine (IBMX)                              Sigma-Aldrich                          28822-58-4                                                                

  Chemical compound                    D-Luciferin, sodium salt                                        Gold Biosciences                       LUCNA-1G                                                                  

  Chemical compound                    Anti-mouse IgG Magnetic microbeads                              Miltenyi                               130-047-101                                                               

  Chemical compound                    EZ-link Sulfo-NHS-biotin                                        Pierce                                 21425                                                                     

  Commercial assay or kit              Alexa Fluor 647 Protein Labeling Kit                            Thermo Fisher Scientific               A20173                                                                    

  Commercial assay or kit              Alexa Fluor 488 Protein Labeling Kit                            Thermo Fisher Scientific               A20181                                                                    

  Commercial assay or kit              Direct cAMP ELISA                                               Enzo Life Sciences                     ADI-900--066                                                              

  Software, algorithm                  Prism                                                           GraphPad                               8.1.1                                                                     

  Software, algorithm                  ImageJ                                                          [Imagej.net](http://Imagej.net)        2.0.0-rc-69/1.52 p                                                        

  Software, algorithm                  MATLAB                                                          MathWorks                              R2014b                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture, expression constructs, and transfections {#s4-1}
------------------------------------------------------

HEK 293 cells (CRL-1573, ATCC, mycoplasma-tested) were cultured in complete growth Dulbecco's modified Eagle's medium (DMEM, Gibco) and supplemented with 10% fetal bovine serum (UCSF Cell Culture Facility). HA-β2AR ([@bib68]; [@bib80]), HA-V2R ([@bib55]), HA-MOR ([@bib84]), HA-V2R-T ([@bib7]; [@bib55]), all described previously, were sub-cloned from Flag-tagged constructs. Nb80-EGFP was previously described ([@bib30]). HA-G(alpha)s, G(beta-1), G(gamma-2) were gifts from Philip Wedegaertner. HA-G(alpha)s-Q227L, a previously described point mutant of Gs that is constitutively active ([@bib46]), was made from the original construct using the QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) with the forward primer 5'-CGATGTGGGCGGCCTGCGCGATGAACGCCGC-3'. Flag-AC1, Flag-AC9 from the Dessauer Lab, were originally described by [@bib22]; [@bib38]; [@bib53]; [@bib54]. Flag-AC9-D442A (Catalytic inactive mutant) was also made from the original construct using QuikChange Kit with the forward primer 5'-CCACTAGTCCAGTGTGGTGGAATTCGCCATGGACTACAAAGACGATGACGAC-3'. Transfections were carried out using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Cells were transfected 48 hr before experiments. siRNA knockdown of AC1 and AC9 expression in HEK293 cells was carried out using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer's protocol. Cells were transfected 72 hr before experiments. Knockdown of AC1 used the siRNA CCGGGCGGTTCAGACCTTCAA and AC9 knockdown used CTGGGCATGAGGAGGTTTAAA.

Primary cultures of human airway smooth muscle cells were prepared as described previously ([@bib75]). Cells were passaged no more than five times using Trypsin-EDTA (Life Technologies) and maintained in 10% FBS in DMEM.

Gs knockout ([@bib63]) and beta-arrestin-1/2 double knockout ([@bib51]) HEK293 cells were previously described. AC3/AC6 double knockout HEK293 cells were also described previously ([@bib60]) and were provided as a generous gift by Drs. Monica Soto-Valasquez and Val Watts (Purdue University). Cells were passaged using PBS-EDTA and maintained in 10% FBS in DMEM.

Cholera Toxin (Sigma) was administered to cells for 16 hr overnight treatment at 10 ng/ml concentration in 10% FBS in DMEM.

We found AC9 trafficking to be environmentally sensitive. Specifically, exposure of cells outside of the incubator for more than 2 min tended to reduce the degree of isoproterenol-stimulated internalization of AC9, without affecting internalization of β2AR. Accordingly, this restriction was consistently adhered to in the present study.

Antibodies {#s4-2}
----------

Antibodies used were rabbit anti-Flag (Sigma), mouse anti-Flag M1 (Sigma), mouse anti-Flag M2 (Sigma), mouse anti-HA 16B12 (Biolegend), rat anti-HA (Roche), goat anti-AC9 (Santa Cruz Biotech), mouse anti-Golgin-97 (Thermo), rabbit anti-calnexin (Cell Signaling), mouse anti-Sodium/Potassium ATPase (Fisher).

Fixed cell confocal imaging {#s4-3}
---------------------------

Cells were transfected with the indicated construct(s) and then plated on glass coverslips coated with poly-L-lysine (0.0001%, Sigma) 24 hr later. For antibody feeding assays, cells were: (1) placed on ice and rinsed with ice-cold phosphate-buffered saline (PBS), (2) labeled by the addition of antibodies diluted 1:1000 in DMEM for 10 min, and (3) rinsed with room temperature PBS and allowed to traffic for 30 min by the addition of 37**°**C fresh media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of β2AR agonist (10 μM isoproterenol, Sigma), V2R agonist (10 µM arginine-vasopressin, Sigma), MOR agonist (10 µM DAMGO, Sigma), or forskolin (10 µM, Sigma). For all assays, cells were rinsed with cold PBS and fixed by incubation in 3.7% formaldehyde (Fisher Scientific) diluted in modified BRB80 buffer (80 mM PIPES, 1 mM MgCl~2~, 1 mM CaCl~2~, pH 6.8) for 20 min at room temperature. Cells were then blocked in 2% Bovine Serum Albumin (Sigma) in PBS with permeabilization by 0.2% triton X-100 (Sigma). Primary antibody labeling was performed by the addition of antibodies diluted 1:1000 in blocking/permeabilization buffer for one hour at room temperature. Secondary labeling was performed by addition of the following antibodies diluted at 1:500 in blocking/permeabilization buffer for 20 min at room temperature: Alexa Fluor 555 or 488 donkey anti-mouse (Invitrogen), Alexa Fluor 555 or 488 donkey anti-rabbit (Invitrogen), Alexa Fluor 488 or 555 goat anti-rat (Invitrogen), or Alexa Fluor 488 donkey anti-sheep (Life Technologies). Specimens were mounted using ProLong Gold antifade reagent (Life Technologies).

Fixed cells were imaged by spinning disc confocal microscope (Nikon TE-2000 with Yokogawa confocal scanner unit CSU22) using a 100X NA 1.45 objective. A 488 nm argon laser and a 568 nm argon/krypton laser (Melles Griot) were used as light sources.

Microscope image acquisition and image analysis {#s4-4}
-----------------------------------------------

Spinning disc images were collected using an electron multiplying CCD camera (Andor iXon 897) operated in the linear range controlled by Micro-Manager software (<https://www.micro-manager.org>). Images were processed at full bit depth for all analysis and rendered for display by converting to RGB format using ImageJ software (<http://imagej.nih.gov/ij>) and linear look up table. The number of endosomes was quantified by thresholding images and the ParticleTracker ImageJ plugin.

Live-cell confocal imaging {#s4-5}
--------------------------

Live cell imaging was carried out using Yokagawa CSU22 spinning disk confocal microscope with a × 100, 1.4 numerical aperture, oil objective and a CO2°C and 37°C temperature-controlled incubator. A 488 nm argon laser and a 568 nm argon/krypton laser (Melles Griot) were used as light sources for imaging EGFP and Flag signals, respectively. Cells expressing both Flag-tagged receptor and the indicated nanobody--EGFP were plated onto glass coverslips. Receptors were surface labelled by addition of M1 anti-Flag antibody (1:1000, Sigma) conjugated to Alexa 555 (A10470, Invitrogen) to the media for 30 min, as described previously. Indicated agonist (isoprenaline, Sigma) or antagonist (CGP-12177, Tocris) (alprenolol, Sigma) were added and cells were imaged every 3 s for 20 min in DMEM without phenol red supplemented with 30 mM HEPES, pH 7.4 (UCSF Cell Culture Facility). Time-lapse images were acquired with a Cascade II EM charge-coupled-device (CCD) camera (Photometrics) driven by Micro-Manager 1.4 (<http://www.micro-manager.org>).

Endosome immunoisolation {#s4-6}
------------------------

Cells were transfected with the indicated construct(s) 48 hr before lysis and plated onto 60 mm cell culture dishes 24 hr before lysis. Cells were allowed to traffic for 30 min by the addition of 37**°**C fresh media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of the indicated agonist. Cells were then placed on ice, washed with ice-cold PBS, and scraped into an isotonic homogenization buffer (10 mM HEPES, 100 mM KCl, 25 mM sucrose, Complete protease inhibitor (Roche), pH 7.2) and passaged 20 times through a 22 G BD PrecisionGlide Needle. Whole cell lysates were then spun down at 1000 G for 10 min at 4°C and the pellets discarded. The supernatant was then bound to Early Endosome Antigen one mouse antibody (1:250, Fisher Scientific) and anti-mouse IgG magnetic microbeads (Miltenyi Biotech) overnight. Endosomes were then bound to magnetic columns which were blocked with 3% BSA and washed with PBS. Proteins in the isolated fraction were eluted with 0.1% Triton-X and characterized by western blot.

Surface biotinylation {#s4-7}
---------------------

Cells were transfected with the indicated construct(s) 48 hr before lysis and plated onto 60 mm cell culture dishes coated with poly-L-lysine (0.0001%, Sigma) 24 hr before lysis. Cells were allowed to traffic for 30 min by the addition of 37**°**C fresh media (DMEM + 10% fetal bovine serum) with or without a saturating concentration of the indicated agonist. Cells were then placed on ice, washed with ice-cold PBS, and then surface labeled with EZ-link Sulfo-NHS-biotin (Pierce) for 30 min, rocking at 4°C. Reaction was then quenched with tris buffered saline (TBS) twice for 10 min. Cells were then placed on ice, washed with ice-cold PBS, and scraped into an isotonic homogenization buffer (10 mM HEPES, 100 mM KCl, 25 mM sucrose, Complete protease inhibitor (Roche), pH 7.2) and passaged 20 times through a 22 G BD PrecisionGlide Needle. Cell lysate was then bound to streptavidin agarose resin (Thermo) overnight. Resin was spun down and the supernatant discarded, resuspended and washed in ice-cold PBS, and characterized by western blot.

Real-time cAMP assay in living cells {#s4-8}
------------------------------------

Real-time analysis of cAMP elevations were carried out in living HEK293 cells and in the absence of phosphodiesterase inhibitors using a were transfected with a plasmid encoding a cyclic-permuted luciferase reporter construct, based on a mutated RIIβB cAMP-binding domain from PKA (pGloSensor-20F, Promega), which produces rapid and reversible cAMP-dependent activation of luciferase activity in intact cells and is capable of detecting cAMP elevations in the absence of phosphodiesterase inhibitors. Cells were plated in 24-well dishes containing approximately 200,000 cells per well in 500 μl DMEM without phenol red and no serum and equilibrated to 37°C in a light-proof cabinet. An image of the plate was focused on a 512 × 512 pixel electron multiplying CCD sensor (Hamamatsu C9100-13), cells were equilibrated for 1 hr in the presence of 250 μg ml^−1^ luciferin (Gold biosciences), and sequential luminescence images were collected every 10 s to obtain basal luminescence values. The camera shutter was closed, the cabinet opened and the indicated concentration of isoprenaline was bath applied, with gentle manual rocking before replacing in the dark cabinet and resuming luminescence image acquisition. In endocytic manipulation experiments, cells were pre-incubated with 30 μM Dyngo-4a (abcam Biochemicals) for 15 min. Every 10 s, sequential images were acquired using Micro-Manager (<http://www.micro-manager.org>) and integrated luminescence intensity detected from each well was calculated after background subtraction and correction for vignetting using scripts written in MATLAB (MathWorks). In each multiwell plate, and for each experimental condition, a reference value of luminescence was measured in the presence of 5 μM forskolin, a manipulation that stimulates a moderate amount of receptor-independent activation of adenylyl cyclase. The average luminescence value---measured across duplicate wells---was normalized to the maximum luminescence value measured in the presence of 5 μM forskolin.

Biochemical assay of cAMP accumulation {#s4-9}
--------------------------------------

A biochemical assay of cAMP accumulation was used to determine the effects of AC mutation on catalytic activity, with high sensitivity and without dependence on subcellular location due to inhibition of cellular phosphodiesterases. Briefly, cells were pre-incubated in the presence of 1 mM IBMX (Sigma) for 30 min at 37°C in Dulbecco\'s modified Eagle\'s medium followed, and then incubated for an additional 10 min in absence or presence of isoproterenol (in the continued presence of IBMX), as indicated. Cells were quickly washed with ice-cold PBS and lysed by exposure to 0.1 M HCl for 10 min at room temperature. The cAMP concentration in lysates was determined using a commercial immunoassay (Direct cAMP ELISA kit, Enzo Life Sciences, Farmingdale, NY) according to the manufacturer's instructions.

Statistical analysis {#s4-10}
--------------------

Results are displayed as the mean of results from each experiment or data set, as indicated in figure legends. The statistical significance between conditions for experiments with two conditions was calculated using paired, two tailed t-tests. All statistical calculations were performed using Excel (Microsoft Office) or Prism (GraphPad). The threshold for significance was p\<0.05 and the coding for significance is reported as follows: (n.s.) p\>0.05, (\*) p≤0.05, (\*\*) p≤0.01.
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Reviewing Editor
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

This work carefully and convincingly demonstrates that Gs activation during β-adrenergic receptor signaling drives endocytosis of a specific isoform of a downstream effector, adenyl cyclase 9, which contributes to cAMP production.

**Decision letter after peer review:**

Thank you for submitting your article \"G protein-regulated endocytic trafficking of adenylyl cyclase type 9\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Suzanne Pfeffer as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). Specifically, we are asking editors to accept without delay manuscripts, like yours, that they judge can stand as *eLife* papers without additional data, even if they feel that they would make the manuscript stronger. Thus the revisions requested below only address clarity and presentation.

Summary:

This study addresses the question of adenyl cyclase (AC) endocytosis during GPCR signaling. Morphological and biochemical experiments primarily in transfected HEK293 cells show that two Gs-coupled GPCRs drive isoform specific endocytosis of AC9 and that Gs is required and sufficient while β-arrestin is not. The internalized AC9 contributes to cAMP production stemming from intracellular receptors. While Gs-induced AC9 endocytosis is independent of cAMP production, the actual mechanism linking Gs activation to AC9 endocytosis remains unknown.

Overall the work shows Gs activation during β-adrenergic receptor signaling drives endosomal localization of the downstream effector AC9. The reviews were positive. The experiments are well-controlled, show mostly clear effects, and are convincing for the system being investigated. Nevertheless, certain conceptual and technical issues were raised that need to be addressed prior to publication.

Essential revisions:

1\) The β2AR is not the prototypical GPCR for studying sustained cAMP generation from endosomes. Although the authors present some data for the V2R that has been previously shown to induce very sustained cAMP responses, it is well-known that several class A or B GPCRs possess this feature as well and to a far greater extent than that observed for the β2AR. If at all possible, the study would benefit from control experiments using another GPCR class A (e.g., TSHR) or class B (e.g., GLP-1R, PAC1R, CTR), which would more broadly determine how generalizable these findings are. Additionally, the authors should put forth a rationale as to why they selected the β2AR for this study as opposed to the more canonical receptors mentioned above.

2\) All fluorescence images shown in the main figures are confocal images, however the quantification data presented in the main figures were obtained from widefield images shown in supplementary figures. While confocal images show a clear internalization of both HA-β2AR and Flag-AC9, the widefield images have high levels of background, which can make particle tracking more difficult. Some concerns about this:

-- What\'s the reason behind choosing to quantify images acquired by widefield and show representative confocal images? The type of microscopy used could affect particle tracking, especially when we consider the lower resolution in widefield compared to confocal.

-- Widefield is a great choice for live cell imaging, however, most of these experiments were done in fixed cells. Confocal will show \"better\" endosomes. Quantification should be done with confocal images.

-- While authors provided a satisfactory statistics analysis, all \"representative\" images and curves (for cAMP production) do not have an \'n\'. How many times were these experiments repeated?

-- Quantification of fluorescence images and representative images should be done with images acquired by the same microscopy method to avoid differences based on the nature of microscopy kind.

10.7554/eLife.58039.sa2

Author response

> Essential revisions:
>
> 1\) The β2AR is not the prototypical GPCR for studying sustained cAMP generation from endosomes. Although the authors present some data for the V2R that has been previously shown to induce very sustained cAMP responses, it is well-known that several class A or B GPCRs possess this feature as well and to a far greater extent than that observed for the β2AR. If at all possible, the study would benefit from control experiments using another GPCR class A (e.g., TSHR) or class B (e.g., GLP-1R, PAC1R, CTR), which would more broadly determine how generalizable these findings are. Additionally, the authors should put forth a rationale as to why they selected the β2AR for this study as opposed to the more canonical receptors mentioned above.

We agree that the B2AR is not a prototype for sustained signaling. Instead, β-2 receptors provide an example of GPCRs which cycle rapidly and continuously through endosomes, activating Gs transiently each round. The B2AR is also widely recognized not to recruit β-arrestins to endosomes, in contrast to some other GPCRs with longer residence in endosomes which have been shown to mediate a sustained cAMP response.

However, we do not believe that these considerations negate the importance of endosomal signaling stimulated by the B2AR. Previously published data (Irannejad et al., 2013, cited in the text), showed that endosomal activation of the B2AR mediates a detectable (albeit moderate) contribution to (transient) global cAMP elevation. We have also shown that this is required for the cAMP-dependent transcriptional response elicited by endogenous B2AR activation (Tsvetanova et al., 2014, also cited). We independently verify in the present study that β-2 receptor activation in endosomes makes a significant (yet rapidly reversible) contribution to the global cellular cAMP response, and provide new data showing that this component of transient cAMP signaling requires AC9.

Nevertheless, we agree that the results summarized above do not necessarily mean that AC9 is also relevant to signaling by GPCRs that mediate sustained Gs activation, and that we failed to address in the initial submission. In the revised manuscript we explicitly note and cite that signaling initiated from endosomes can be transient or sustained (Introduction, second paragraph), and that the V2 vasopressin receptor (V2R) mediates sustained signaling (--subsection "AC9 trafficking is stimulated by GPCRs coupled to Gs but not Gi", first paragraph). We demonstrate in the present study that V2Rs are indeed capable of driving AC9 trafficking in 293 cells when recombinantly expressed in these cells, similarly to recombinantly expressed B2ARs which define our primary focus.

We also show that a V2R truncation mutant can drive AC9 trafficking. We focused on this observation as an initial clue to a separation between receptor and AC9 trafficking. However this mutant receptor is also well known to lose its 'class B' phenotype (β-arrestin recruitment to endosomes) and recycle more rapidly than wild-type V2R. We have modified the text to explicitly point this out in the revised Results section (--subsection "AC9 trafficking is stimulated by GPCRs coupled to Gs but not Gi", last paragraph). We believe that these results provide additional, independent support for our conclusion that AC9 trafficking is not restricted to the β-2 adrenergic receptor or to rapidly recycling / transiently signaling GPCRs. This is also consistent with the ability of receptor-independent activation of Gs (mutationally or using cholera toxin) to stimulate AC9 trafficking, as was already shown and discussed in the manuscript.

> 2\) All fluorescence images shown in the main figures are confocal images, however the quantification data presented in the main figures were obtained from widefield images shown in supplementary figures. While confocal images show a clear internalization of both HA-β2AR and Flag-AC9, the widefield images have high levels of background, which can make particle tracking more difficult. Some concerns about this:
>
> -- What\'s the reason behind choosing to quantify images acquired by widefield and show representative confocal images? The type of microscopy used could affect particle tracking, especially when we consider the lower resolution in widefield compared to confocal.
>
> -- Widefield is a great choice for live cell imaging, however, most of these experiments were done in fixed cells. Confocal will show \"better\" endosomes. Quantification should be done with confocal images.
>
> -- While authors provided a satisfactory statistics analysis, all \"representative\" images and curves (for cAMP production) do not have an \'n\'. How many times were these experiments repeated?
>
> -- Quantification of fluorescence images and representative images should be done with images acquired by the same microscopy method to avoid differences based on the nature of microscopy kind.

The reason that we show wide field images is to verify the trafficking behavior over large cell 'lawns' and to indicate that the trafficking phenotype is robust and consistent across cells. We also think this is useful because, as the reviewers indicate, widefield is less sensitive for detecting internalization effects relative to confocal (which can emphasize internal structures depending on the plane of section). We think the fact that one can easily see the trafficking phenotype with low-mag widefield imaging is significant and may be relevant for those investigators who lack routine access to a confocal microscope or objectives with sufficiently high magnification / numerical aperture to resolve individual endosomes as the reviewers indicate. Actually we do show (in the main figures) multiple examples of such higher-resolution images, but this is not the point of including the lower resolution images of cell lawns in the supplement. We also agree that quantifying more confocal images could provide additional support, but again this was not the purpose of including widefield images. In fact we believe that the (two) biochemical approaches used (surface biotinylation and endosome isolation) more incisively establish internalization of AC9. To clarify this, in the revised manuscript we more fully explained our rationale for showing lower-resolution images in data supplement (subsection "Regulated and isoform-selective trafficking of AC9 to endosomes", second paragraph).
